Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc. reports developments as a biopharmaceutical company developing targeted small-molecule medicines for brain disorders and symptoms linked to excess neural excitability. Recurring news centers on its KCC2 direct-activator portfolio, including OV350, OV4071 and next-generation candidates, as well as OV329, a next-generation GABA-aminotransferase inhibitor being developed for treatment-resistant seizures and related rare epileptic disorders.
Company updates also cover clinical and translational data, regulatory clearances for early-stage studies, R&D events, financial results, private-placement and warrant-related capital actions, investor conference participation, and leadership or governance changes tied to the advancement of its CNS pipeline.
Ovid Therapeutics (Nasdaq: OVID) reported second quarter 2026 results and major pipeline and corporate developments. Cash, cash equivalents and marketable securities were $169.8 million as of June 30, 2026, and the company expects its financial runway to extend into 2029.
Ovid is advancing OV4071, a first-ever oral direct KCC2 activator, in an ongoing Phase 1 study, with a ketamine challenge study planned for the second half of 2026 and Phase 2 proof-of-concept in acute schizophrenia targeted for 2027. The company also initiated Phase 2 and photosensitivity proof-of-concept studies for OV329, a next-generation GABA-AT inhibitor, across multiple seizure disorders.
A new Perceptive Advisors–backed company acquired global rights to soticlestat; Ovid obtained equity in the new company and is eligible for up to $294.5 million in potential milestones plus low- to mid-single digit royalties. Second quarter 2026 revenue was $0.7 million versus $6.3 million a year earlier, with net loss widening to $15.0 million.
Ovid Therapeutics (Nasdaq: OVID) announced several senior leadership changes to support its next phase of development. Kevin Norrett will join as Chief Business Officer, Charles Carter is promoted to Chief Financial Officer, and former CFO Jeffrey Rona will remain an advisor through 2027.
Eliseo Salinas becomes Executive R&D Advisor, and Victoria Fort is promoted to Chief Strategy Officer. According to Ovid Therapeutics, Fort previously led two financings that extended the company’s cash runway into 2029.
Ovid Therapeutics (Nasdaq: OVID) announced that management will participate in two June 2026 investor conferences focused on neurology.
Events include the Oppenheimer CNS & Neuro-Muscular Summit on June 10 at 3:45 p.m. and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15, with live and archived webcasts via its investor website.
Ovid Therapeutics (Nasdaq: OVID) appointed physician-scientist and biotech entrepreneur Anna Greka, M.D., Ph.D. to its Board of Directors, effective June 15, 2026. She will Chair the new Science and Technology Committee and join the Compensation Committee.
Greka leads Ladders to Cures, is a Core Institute Member and executive leader at the Broad Institute, and Professor of Medicine at Harvard Medical School and Mass General Brigham. She has founded and advised multiple biotech companies, including ventures whose assets were acquired by Bristol Myers Squibb and AstraZeneca.
Ovid Therapeutics (Nasdaq: OVID) reported Q1 2026 business and financial updates, highlighting pipeline progress and strengthened capital.
OV329 showed favorable safety up to 9 mg and is moving into Phase 2 studies in treatment‑resistant epilepsies and new pediatric programs. OV4071, an oral KCC2 activator, began Phase 1 dosing. Recent PIPE financings and warrant exercises raised about $113.9 million, bringing cash and securities to $165.6 million on March 31, 2026 and extending projected runway into 2029. Q1 net loss was $17.0 million on operating expenses of $17.8 million.
Ovid Therapeutics (Nasdaq: OVID) will host a KCC2 Deep Dive R&D event on Tuesday, April 14, 2026 at 9:30 am ET in New York, with a simultaneous webcast. The session will review Ovid's first-in-class KCC2 portfolio, pharmacodynamic data, translational and clinical strategy, and market potential.
Speakers include CEO Meg Alexander, independent clinicians, translational experts, and leading neuroscientists; a webcast replay will be archived for 90 days.
Ovid Therapeutics (Nasdaq: OVID) reported new safety and PK data for OV329 (7 mg) supporting dose selection and potential best-in-category profile, announced expansion into tuberous sclerosis complex seizures and infantile spasms funded by a $60.0M private placement, and cleared OV4071 Phase 1 in Australia.
The company held $90.4M at year-end 2025, expects Phase 2 OV329 to start Q2 2026, and noted potential $53.9M from Series A warrant exercise that could extend runway into 2029.
Ovid Therapeutics (Nasdaq: OVID) announced a $60.0 million PIPE financing expected to close on or about March 19, 2026. The financing is led by Point72 and includes existing investors.
The company is selling 19,154,321 common shares at $2.01 and pre-funded warrants to purchase 10,701,710 shares at $2.009 each, with an exercise price of $0.001. Net proceeds will support expansion of OV329 into tuberous sclerosis complex and infantile spasms and general R&D; placement agents include Leerink, Oppenheimer & Co. and LifeSci Capital. Registration rights for resale were agreed with investors.
Ovid Therapeutics (Nasdaq: OVID) said management will present at three investor conferences between Feb 25 and Mar 11, 2026, with scheduled times listed for each event.
A live webcast will be available at the company’s Events & Presentations page and an archived replay will be posted for about 30 days.
Ovid Therapeutics (NASDAQ: OVID) reported Phase 1 results for OV350, the first-ever KCC2 direct activator dosed in humans. The randomized, placebo-controlled single-ascending dose study in 16 healthy participants met primary objectives for safety, tolerability, and pharmacokinetics. No treatment-related serious adverse events were reported and pharmacokinetics matched predictions. Exploratory qEEG showed central activity consistent with expected KCC2 modulation and brain exposure. The IV program will not advance further; Ovid is prioritizing oral KCC2 activators, including OV4071 (20-fold more potent than OV350) with a regulatory filing targeted in Q1 2026 and clinical start planned for Q2 2026.